Despite accelerating progress towards schistosomiasis control in sub-Saharan Africa, several age groups have been eclipsed by current treatment and monitoring strategies that mainly focus on school-aged children. As schistosomiasis poses a threat to people of all ages, unfortunate gaps exist in current treatment coverage and associated monitoring efforts, preventing subsequent health benefits to preschool-aged children as well as certain adolescents and adults. Expanding access to younger ages through the forthcoming pediatric praziquantel formulation and improving treatment coverage in older ages is essential. This should occur alongside formal inclusion of these groups in large-scale monitoring and evaluation activities. Current omission of these age groups from treatment and monitoring exacerbates health inequities and has long-term consequences for sustainable schistosomiasis control.

尽管撒哈拉以南非洲在血吸虫病控制方面取得了加速进展，但当前主要针对学龄儿童的治疗和监测策略已使几个年龄组黯然失色。由于血吸虫病对所有年龄段的人构成威胁，不幸的是，目前的治疗覆盖面和相关的监测工作存在差距，从而阻碍了学龄前儿童以及某些青少年和成人的后续健康益处。通过即将推出的儿科吡喹酮制剂扩大对年轻人的使用范围并提高老年人的治疗覆盖率至关重要。这应该与将这些群体正式纳入大规模监测和评估活动一起发生。